Genetic polymorphisms associated with antiepileptic metabolism

Frontiers in Bioscience - Elite

Volumn 6 E, Issue 2, 2014, Pages 377-386

  Lopez Garcia, Miguel A ^a,b   Feria Romero, Iris A ^b   Fernando Serrano, Hector ^a   Escalante Santiago, David ^b   Grijalva, Israel ^b   Orozco Suarez, Sandra ^b  

^a UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Alleles; Anticonvulsants; CYP450 genes; DNA polymorphism; Drug metabolism; Epilepsy; Pharmacogenetics; Review

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4;

DRUG METABOLISM; DRUG RESPONSE; EPILEPSY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; REVIEW;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HUMANS; METABOLIC NETWORKS AND PATHWAYS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PUBMED;

EID: 84904464389     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e713     Document Type: Review

References (76)

1. Porter R, Meldrum BS, Porter RJ and Meldrum BS. Antiseizure Drugs, In: BG Katzung, eds. Basic and Clinical Pharmacology. 8th ed. NY. Lange Medical Books, pp 395-17 (2001)
2. Browne TR, Holmes GL. Epilepsy. N Engl J Med 344 (15), 1145-5 (2001)
3. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 46, 224-35 (2005)
4. Sander JW. Some aspects of prognosis in the epilepsies: a review. Epilepsia 34, 1007-16 (1993)
5. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34, 109-22 (1999)
6. Schmidt D., Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46 (6), 858-77 (2005)
7. Rogawski MA. The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. Epilepsia 54 Suppl 2, 33-40 (2013)
8. Löscher W. Potschka H. Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs. J Pharmacol Exp Ther 301, 7-14 (2002)
9. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42 (1996)
10. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50, 1-23 (2009). DOI: 10.1111/j.1528-1167.2008.01716.x
11. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 8, 371-82 (2012)
12. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-71 (2000)
13. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348 (15), 1442-8 (2003)
14. Zimprich F, Sunder-Plassmann R, Stogmann E, Gleiss A, Dal-Bianco A, Zimprich A, Plumer S, Baumgartner C, Mannhalter C. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63 (6), 1087-9 (2004)
15. Seo T, Ishitsu T, Ueda N, Nakada N, Yurube K, Ueda K, Nakagawa K. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 7 (4), 551-61 (2006)
16. Tate SK, Depondt Ch, Sisodiya SM, Cavalleri GL, Schorge S, Soranzo N, Thom M, Sen A, Shorvon SD, Sander JW, Wood NW, Goldstein DB. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS 102 (15), 5507-12 (2005)
17. Holland KD, Kearney J, Glauser TA, Buck G. Keddache M, Blankston JR, Glaaser L., Kass J, Meisler MH. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci. Lett 433, 65-70 (2008)
18. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2, 347-56 (2003)
19. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45, 525-38 (1998)
20. Lazarowski A, Czornyj L, Lubieniecki F, Vazquez S, D' Giano C, Sevlever G. Multidrug resistence (MDR) Proteins develops RE phenotype. Clinical and experimental evidences. Current Drug Therapy 1, 291-239 (2006)
21. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8, E101-11 (2006)
22. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, Wang DM. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 y CYP2D6 in Han Chinese. Pharmacogenomics J 9, 380-94 (2009)
23. Ingelman-Sundberg M, Sim SC. Pharmacogenetics biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem Biophys Res Commun 396, 90-94 (2010)
24. Rodríguez-Arcas MJ, García-Jiménez E, Martínez-Martínez F, Conesa-Zamora P. Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs. Farm Hosp 35, 84-92 (2010)
25. Iniesta R, Guinóa E, Moreno V. Análisis estadístico de polimorfismos genéticos en estudios epidemiológicos. Gac Sanit 19, 333-41 (2005)
26. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-71. (2000)
27. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37, 269-96 (1997)
28. Szoeke CE, Newton M, Wood JM, Goldstein D, Berkovic SF, OBrien TJ, Sheffield LJ. Update on pharmacogenetics in epilepsia: a brief review. Lancet Neurol 5, 189-96 (2006)
29. Nelson DR. Cytochrome P450 and the individuality of species. Arch Biochem Biophys 1, 1-10 (1999)
30. Zanger U, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/ genomics of human cytocromes P450 involved in drug biotransformation. Anal Bioanal Chem 392, 1093-1108 (2008).
31. Rodríguez-Antona C, Ingelman-Sunberg M. Cytochrome P450 pharmacogenetics and cáncer. Oncogene 25, 1679-1690 (2006)
32. Humma LM, Terra SG. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Am J Health Syst Pharm. 59, 1241-52 (2002)
33. Glauser TA. Biomarkers for antiepileptic drug response. Biomark Med 5, 635-41 (2011)
34. Gardiner SJ, Begg EJ. Pharmacogenetics, drugmetabolizing enzymes, and clinical practice. Pharmacol Rev 58, 521-90. (2006)
35. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 6 (17), 1895-903 (1967)
36. Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta 381, 26-31 (2007)
37. López M, Guerrero J, Jung-Cook H, Alonso ME. CYP2D6 genotype and phenotype determination in a Mexican mestizo population. Eur J Clin Pharmacol 61, 749-54 (2005)
38. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM . CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70, 552-60 (2001)
39. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-43 (2002)
40. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28, 1287-93 (2010)
41. Isaza CA, Henao J, Lopez AM, Cacabelos R. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 22, 695-705 (2000)
42. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 9, 217-28 (1999).
43. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29, 192-09 (1995)
44. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54, 1257-70 (2002)
45. Sosa-Macías M, Llerena A. Cytochrome P450 genetic polymorphisms of Mexican indigenous populations Drug Metabol Drug Interact 28, 193-208 (2013). DOI:10.1515/dmdi-2013-0037
46. Yang ZF, Cui HW, Hasi T, Jia SQ, Gong ML, Su XL. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. Genet Mol Res 9,1844-51 (2010)
47. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21, 419-26 (2007)
48. Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr 69, 153-8 (2011)
49. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA.Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64 (1997)
50. Liu XL, Wang ZJ, Yang Q, Ge HL, Gao F, Liu YY, Shi DM, Zhao YX, Zhou YJ. Impac of CYP2C19 polimorphism and smoking on response, to clopidogrel in patients with stable coronary artery disease. Chin Med J 123, 3178-83 (2010)
51. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79, 103-13 (2006)
52. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54, 1271-94 (2002)
53. Shih PS, Huang JD. Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30, 1491-6 (2002)
54. Dickinson R, Hooper W, Patterson M, Eadia M, Maguire B. Extent of urinary excretion of phydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 7, 283-9 (1985)
55. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 36, S8-13 (1995)
56. Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Bergmann JF, Mouly S. The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin. J Clin Psychopharmacol 32, 429-31 (2012)
57. Van Der Weide J, Steijns LS, Van Weelden MJ, De Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-91 (2001)
58. Ninomiya H, Mamiya K, Matsuo S, Ieiri I, Higuchi S, Tashiro N. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit 22, 230-2 (2000)
59. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther, 70, 391-4 (2001)
60. Mamiya K, Hadama A, Yukawa E, Ieiri I, Otsubo K, Ninomiya H, Tashiro N, Higuchi S. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol 55, 821-5 (2000)
61. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52, 349-55 (2001)
62. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 35, 1032-41 (2007)
63. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7 Drug Metab Dispos 30, 883-891 (2002)
64. Jaramillo NM, Galindo IF, Vázquez AO, Cook HJ, Llerena A, López ML. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response Drug Metabol Drug Interact 9, 1-13 (2014)
65. Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. . Functional characterization of CYP3A4.1.6: catalytic activities toward midazolam and carbamazepine. Xenobiotica 39, 140-7 (2009)
66. Maekawa K, Harakawa N, Yoshimura T, Kim SR, Fujimura Y, Aohara F, Sai K, Katori N, Tohkin M, Naito M, Hasegawa R, Okuda H, Sawada J, Niwa T, Saito Y. CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 38, 2100-04 (2010)
67. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, Leppik IE, Lamba JK. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy Pharmacogenomics 14, 35-45 (2013)
68. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. Clin Pharm Ther 34, 569-74 (2009)
69. Seo T, Nakada N, Ueda N, Hagiwara T, Hashimoto N, Nakagawa K, Ishitsu T . Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther 79, 509-10 (2006)
70. Bourgeois BF. Drug interaction profile of topiramate. Epilepsia; 37, S14-7 (1996)
71. Contin M, Riva R, Albani F, Avoni P, Baruzzi A. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 24, 332-7 (2002)
72. Contin M, Albani F, Riva R, Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs . Ther Drug Monit 26, 375-9 (2004)
73. Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 32, 340-53 (2012)
74. Soundararajan CC, Adhin A, Tripathi M, Prasad HK, Jain S, Vivekanandhan S. Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians. J Neural Transm 113, 1873-6 (2006)
75. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41, 913-58 (2002)
76. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61 (3), 246-55 (2006)